Preoperative Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes: A Prospective Multi-Institutional Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,282
- 试验地点
- 3
- 主要终点
- all-cause mortality
研究概览
简要总结
Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria;
- •age > 18 years;
- •primary malignant glioma;
- •the duration of follow-up > 3 months;
- •available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization.
- •Exculsion Criteria:
- •current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition;
- •prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;
排除标准
- 未提供
结局指标
主要结局
all-cause mortality
时间窗: 16 years
For this study, the endpoint was all-cause mortality. Time zero was set at the time of resection of the primary tumor.
次要结局
未报告次要终点
研究者
Yonggao Mou
Clinical Professor
Sun Yat-sen University